PrEP on the spot: HIV prevention delivered at syringe services shows promise

NCT ID NCT04782180

Completed Prevention Sponsor: University of Miami Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested whether giving the HIV prevention pill Descovy (PrEP) right at a syringe services program helps people stay HIV-negative. 90 adults who use the syringe program and tested negative for HIV took part. Researchers measured drug levels in blood to see if participants were taking the pills regularly. The goal is to make PrEP easier to access for people at high risk.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Descovy (emtricitabine/tenofovir alafenamide) tablet
What this could lead to: If successful, this approach could make it easier for people who use drugs to get HIV prevention medication, reducing new infections.
What could go wrong: This is a small pilot study (90 people) without a comparison group, so results may not apply broadly. Adherence to daily pills can be challenging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS substance-related disorder HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV SUBSTANCE USE DISORDERS

Contacts and locations

Locations

University of Miami

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.